We carried out univariate and bivariate linkage analyses to identify genomic regions that may influence plasma levels of C-reactive protein (CRP) and fibrinogen and exert pleiotropic effects on both traits. Subjects included African American (AA, n ¼ 1310, mean age 62.779.4 years) and non-Hispanic white (NHW, n ¼ 796, mean age 58.479.8 years) belonging to hypertensive sibships. Plasma CRP was measured by an immunoturbidimetric assay and fibrinogen by the Clauss method. Genotyping was performed at 366 microsatellite marker loci spaced B10 cM apart across the 22 autosomes. Estimation of heritability and linkage analyses was carried out using a variance components approach. Significant heritability was noted for CRP (0.38 in AA and 0.37 in NHW subjects) and fibrinogen (0.44 in AA and 0.28 in NHW subjects). Significant genetic correlation between CRP and fibrinogen was present in both AA (0.39) and NHW (0.40) subjects. In univariate linkage analysis, the maximum logarithm of odds (LOD) score for CRP was on chromosome 10q22 in NHW (LOD ¼ 1.69, 106.75 cM, P ¼ 0.0026) and for fibrinogen on chromosome 2 in AA (LOD¼ 2.14, 55.5 cM, P ¼ 0.0009) subjects. Bivariate linkage analysis demonstrated suggestive evidence of linkage (defined as LOD scoreX2.87) for both traits on chromosome 12 (LOD ¼ 3.44, 152.16 cM, P ¼ 0.0003) in AA and on chromosome 21 (LOD ¼ 3.03, 13.05 cM, P ¼ 0.0008) in NHW subjects. Plasma CRP and fibrinogen levels are heritable and genetically correlated. Linkage analyses identified several chromosomal regions that may harbour genes influencing CRP and fibrinogen levels and exert pleiotropic effects on both traits.
Introduction
C-reactive protein (CRP) and fibrinogen are acute phase reactants, markers of inflammation and risk factors for cardiovascular disease (CVD).
1,2 Both proteins have multiple functions. For example, CRP is a pattern-recognition molecule that modulates phagocytosis and binds phosphocholine, cell debris, the surface of pathogens, oxidized low-density lipoproteins and the immunoglobulin receptor. 3 CRP modulates immune response including cytokine production and activation of complement, regulates cell adhesion molecule expression on the endothelium and inhibits endothelial nitric oxide synthase expression. 3, 4 Fibrinogen is a major determinant of plasma viscosity, it mediates platelet aggregation 5 and stimulates smooth muscle cell migration and proliferation. 6 Both proteins have been implicated in the pathogenesis of CVD, and several large prospective studies have shown that CRP and fibrinogen levels are independent risk factors for CVD.
1,2 CRP accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. 7 Young apparently healthy adults with a family history of early myocardial infarction have higher plasma fibrinogen levels than subjects without such a history, suggesting that genetic influences on plasma fibrinogen may contribute to the familial risk of CVD. 8 High concentrations of fibrinogen or fibrin-related antigen have been found in atherosclerotic lesions, 9 and fibrin stimulates smooth muscle cell migration and proliferation. 6 CRP and fibrinogen are synthesized in hepatocytes and are principally regulated at the transcriptional level by cytokines, especially interleukin-6 (IL6, chromosome 7p21) and interleukin-1 (IL1A, chromosome 2q14). 3 Both CRP and plasma fibrinogen levels are influenced by age, sex, smoking, alcohol consumption, physical activity and diabetes. 10 Hereditary influences on CRP and fibrinogen levels have also been reported in familial and twin studies. [11] [12] [13] Polymorphisms in CRP and fibrinogen genes modify their respective plasma levels, [14] [15] [16] but genes at remote loci that may regulate CRP and/or fibrinogen levels remain largely unknown. We therefore carried out linkage analyses to identify genomic regions that may influence the individual traits. Because CRP and fibrinogen are correlated traits, we also carried out bivariate linkage analyses to identify loci with pleiotropic effect on both traits.
Materials and methods

Sample
Subjects were participants in the Genetic Epidemiology Network of Arteriopathy (GENOA) study, a multicentre community-based study of hypertensive sibships that aims to identify genes influencing blood pressure levels and the development of target organ damage due to hypertension. The details of the study design have been published elsewhere. 17 Briefly, in the initial phase of the GENOA study (September 1995 -June 2001 , sibships containing at least two individuals with essential hypertension diagnosed before age 60 years were enrolled in Jackson, MS (African American (AA) subjects, n ¼ 1854) and in Rochester, MN (non-Hispanic white (NHW) subjects, n ¼ 1583). In Jackson, MS, probands with essential hypertension diagnosed o60 years of age were identified from participants in the Atherosclerosis Risk in Communities Study, a multicentre study of risk factors and occurrence of atherosclerotic disease. In Rochester, MN, probands were identified through the Rochester Epidemiology Project and the Mayo Medical Center diagnostic index for residents of Olmsted County, MN. Once a sibship was ascertained, all sibs within a sibship were invited to participate. Between December 2000 and December 2004, 1173 of the original GENOARochester participants and 1350 of the original GENOA-Jackson participants returned for a second study visit to undergo measurement of risk factors including two circulating markers of inflammation-CRP and fibrinogen. Complete genotypic and phenotypic data for the present analyses were available in 1319 Jackson and 826 Rochester participants in phase II. The study was approved by the Institutional Review Board of the University of Jackson, MS and Mayo Clinic Rochester, MN. Written informed consent was obtained from each participant.
Height was measured by stadiometer, weight by electronic balance, and body mass index (BMI) was calculated as kg m À2 . Resting systolic blood pressure and diastolic blood pressure levels were measured in the right arm with random-zero sphygmomanometers. Three measures at least 2 min apart were taken and the average of the second and third measurements was used in the analysis. Participants were considered diabetic if they reported treatment with insulin or oral hypoglycaemic agents or if they reported a physician diagnosis of diabetes but were not currently taking a pharmacological agent to control glucose levels. Information about the use of lipid-lowering medications was obtained at the time of the study visit. Blood samples were obtained by venipuncture after an overnight fast. CRP level was determined by a highly sensitive immunoturbidimetric assay. 18 Fibrinogen was determined by the Clauss method. 19 The inter-assay coefficients of variations were 2.270.4% for CRP and 5.070.8% for fibrinogen.
Genotyping DNA from all study participants was extracted from 10 ml EDTA-treated blood, according to standard procedures. Microsatellite markers (CHLC/Weber screening set 9.0, n ¼ 366) were genotyped by standard PCR-based methods by the Mammalian Genotyping Center of the Marshfield Medical Research Foundation as was reported previously. 20 For the Jackson sample, 338 autosomal microsatellite markers (CHLC/Weber screening set 6.0) were genotyped and independently scored by two separate individuals at the University of Texas-Houston Health Science Center. For the Rochester sample, 381 autosomal microsatellite markers (CHLC/Weber screening set 9.0) were genotyped by the Mammalian Genotyping Center of the Marshfield Medical Research Foundation. The Marshfield Medical Research Foundation (research.marshfieldclinic. org/genetics/) provided marker order and genetic map distances. We used the Lange and Goradia algorithm as implemented in the PedCheck software to ascertain inconsistencies of the genotypes with pedigree structure, and any instances that could not be resolved were considered genotyping errors. Identical twins and non-sibs were identified using ASPEX and then removed.
Statistical analyses
Plasma CRP levels had excessive skew and kurtosis and were therefore natural log transformed. Log CRP and fibrinogen levels were adjusted for age, sex, BMI, diabetes, history of smoking, statin use and oestrogen use in women. Genetic and environmental correlations between the adjusted traits were estimated by variance decomposition using maximum likelihood methods, and the total phenotypic correlations between traits were calculated based on genetic and environmental correlations. Heritability (h 2 ) of each trait was calculated as the proportion of the total phenotypic variance due to additive genetic effects after adjustment for covariates. 21 Univariate and bivariate linkage analyses were carried out using the Variance Components approach implemented in the R library 'Multic', 22 which employs a multivariate variance components approach that is an extension of the univariate approach described by Amos and de Andrade et al. 23, 24 Further details regarding multivariate linkage analyses have been previously published. 25 Multipoint identity-by-descent (IBD) sharing among pairs of relatives was calculated using the SIM-WALK2 software program. 26 This program estimates multipoint IBD probabilities using an alternate Markov chain Monte Carlo algorithm to efficiently accommodate large sibships and provides estimates in agreement with deterministic methods.
To test for genetic linkage, a likelihood ratio test (LRT) was used in which the LRT is defined as À2 Â ((log likelihood under the null hypothesis)À(log likelihood under the alternative hypothesis)). Under the null hypothesis, the linked gene parameter(s) are restricted to 0 (s g Á ij are 0 for all i, j ). For the bivariate linkage analysis, the distribution of the bivariate test that the linked-gene components and covariance are 0 is a mixture of 1/4 w 0 2 , 1/2 w 1 2 and 1/4 w 3 2 as described by Self and Liang. 27 All logarithm of odds (LOD) scores for the multipoint linkage analyses were calculated from the LRT values as LRT/(2 Â ln (10)). For the univariate linkage analyses of CRP and fibrinogen, we considered multipoint LOD scores X3.00 as statistically significant evidence of linkage, X2.00 as suggestive evidence, and X1.30 as tentative evidence of linkage. These multipoint LOD score thresholds correspond to genome-wide P-values of p0.0001, p0.001 and p0.007, respectively. Bivariate linkage analyses were carried out for a combination of the traits. To achieve levels of statistical significance comparable to the univariate linkage thresholds, we considered bivariate LOD scores X4.00 as statistically significant evidence of linkage, X2.87 as suggestive evidence and X2.06 as tentative evidence of linkage. These higher bivariate thresholds were calculated using asymptotic values of a mixture of 1/4 w 0 2 , 1/2 w 1 2 and 1/4 w 3 2 distribution. We considered a region to have possible pleiotropic effects if the bivariate LOD score was at least 2.06 and the P-value was less than for either of the univariate maxima.
Results
The 1310 AA subjects belonged to 672 sibships that included 1145 sibpairs; there were 308 singletons, 1206 sibships of size 2, and 158 sibships of size 3 or greater. Women comprised 71% of the subjects, 78.5% were hypertensive, 28.8% had diabetes and 19.3% were on lipid-lowering medications ( Table 1) . The 796 NHW subjects belonged to 369 sibships and included 812 sibpairs; there were 95 singletons, 173 sibships of size 2 and 101 sibships of size 3 or greater. Women comprised 58.8% of the subjects, 73.1% were hypertensive, 14.8% had diabetes and 31.4% were on lipid-lowering medications (Table 1 ). Significant ethnic differences were noted for all of the subject characteristics (except height) listed in Table 1 . Plasma levels of CRP and fibrinogen were significantly higher in AA subjects. These results justified stratification by ethnicity when doing the analyses.
Heritability and genetic correlations Statistically significant (Po0.0001) heritability (h 2 ) was noted for CRP (0.38 in AA and 0.37 in NHW subjects) and fibrinogen (0.48 in AA and 0.28 in NHW subjects) after adjustment for age, sex, BMI, smoking history, diabetes and statin use ( Table 2 ). Significant (Po0.0001) genetic correlations were present between CRP and fibrinogen (r G ¼ 0.39 in AA and r G ¼ 0.35 in NHW subjects). Significant (Po0.0001) phenotypic correlation were present between CRP and fibrinogen (0.46 in AA and 0.40 in NHW subjects; Table 2 ).
Linkage analyses
There was tentative or suggestive evidence of linkage (defined as multipoint LOD score 42.0 and 1.3-2.0, respectively) for CRP on chromosome 9q34 (159.99 cM, LOD ¼ 1.334, P ¼ 0.0066) in AA and on chromosomes 1q25 (185.0 cM, LOD ¼ 1.326, P ¼ 0.0067) and 10q22 (106.75 cM, LOD ¼ 1.692, P ¼ 0.0026) for NHW subjects Figure 1 ). In AA subjects, bivariate linkage analyses identified a region near D12S2078 on chromosome 12q24 (152.2 cM, bivariate LOD ¼ 3.43, P ¼ 0.0003) (Figure 2a ; Table 3 ) that may influence plasma levels of both traits. In NHW subjects, bivariate linkage analyses identified a region near D21S1437 on chromosome 21q21 (13.05 cM, bivariate LOD ¼ 3.03, P ¼ 0.0008) (Figure 2b ; Table 3 ) that may have pleiotropic effects on plasma CRP and fibrinogen.
Potential candidate genes in the linked regions
We retrieved genes located in the LOD-1 support interval of each linkage peak using the University of California Santa Cruz human genome annotation database (genome.ucsc.edu). There were 920 genes under the seven linkage signals (including univariate and bivariate signals) for AA subjects and 840 genes under the four linkage signals for NHW subjects. We identified potential candidate genes that interact directly with CRP and the genes encoding three polypeptide chains of fibrinogen a (FGA), b (FGB) and g (FGG) under the linkage signals (Table 4) , using the Ingenuity Pathway Analysis (IPA; www.ingenuity.com) software. IPA is a knowledge-based discovery tool and the largest curated database of previously published findings on mammalian biology. [43] [44] [45] The CRP gene was located under the linkage signal for CRP on chromosome 1q21-23, but we did not find a linkage signal for the region on chromosome 4q28 that harbours the genes encoding fibrinogen peptides (FGA, FGB and FGG). Seven genes (FCER1G, SELP, SERPINC1, ITGB3, GH1, SCARB1 and TCF1) involved in the expression, activation and degradation of fibrinogen were identified under the linkage signals for plasma fibrinogen (Table 4) .
Discussion
Cardiovascular disease (CVD) is determined by genetic and environmental factors and their interactions. Although family-based studies suggest an important pathogenic role for genetic factors, only a small proportion of CVD can be attributed to single gene defects such as homozygous familial hypercholesterolaemia. The nature of additional contributing genes remains largely unknown. Identification of genetic factors that influence intermediate 'traits' such as plasma CRP and fibrinogen levels-markers of increased CVD risk implicated in the pathogenesis for CVD 1, 2 -may facilitate elucidation of disease mechanisms and the development of new strategies for risk stratification and disease treatment and prevention.
Hereditary influences on CRP and fibrinogen levels have been previously reported. [11] [12] [13] In the present study of sibships ascertained based on hypertension, we found plasma levels of CRP and fibrinogen to be moderately heritable, consistent with earlier studies. [11] [12] [13] 46, 47 The heritability of plasma fibrinogen levels was greater in AA subjects (h 2 ¼ 0.44) than in NHW (h 2 ¼ 0.28), suggesting a stronger additive genetic contribution to this trait in AA subjects. Significant phenotypic and genetic correlations between plasma CRP and fibrinogen levels were present Linkage analyses for inflammatory markers K Ding et al in both AA and NHW subjects, indicating that shared genes and environment influence inter-individual variation in CRP and fibrinogen levels. Polymorphisms in CRP and fibrinogen genes have been shown to modify their respective plasma levels, [48] [49] [50] [51] although the evidence that these polymorphisms influence susceptibility to CVD is controversial. 49, 50 Genes at remote loci that may regulate CRP and/or fibrinogen levels remain largely unknown. Using univariate linkage analysis, we demonstrated either suggestive or tentative evidence of linkage at several loci for plasma CRP and fibrinogen levels in both AA and NHW subjects ( Figure 1 ; Table 3 ). Bivariate linkage analysis identified additional genomic loci that may influence both traits. Linkage analyses for inflammatory markers K Ding et al
Linkage analyses to identify genomic regions that influence plasma CRP and/or fibrinogen levels have been previously reported. The Framingham Heart Study reported linkage analyses for plasma fibrinogen levels and CRP levels, as well as IL6, CCL2 and ICAM1. 52, 53 Suggestive linkage for fibrinogen was found on chromosomes 2, 10 and 20 with the highest LOD score of 2.4 at 87 cM on chromosome 2. 52 For CRP, a region on chromosome 14 showed a LOD score of 1.58 at 97 cM. Keenan et al.
47 noted significant evidence of linkage for plasma CRP levels on chromosome 5p15 (LOD ¼ 3.41, P ¼ 0.013) in 317 non-diabetic and 177 type-2 diabetic family members. No overlap was found between these previously reported genomic loci and the ones identified in our study, indicating that the genetic heterogeneity and ethnic diversity of human populations hinder the replication of results. We did find a modest linkage signal in NHW subject in the vicinity of the CRP locus on chromosome 1q21-23. Previous reports have also demonstrated that CRP variants are associated with plasma CRP levels in the general population. 15, 16, 49, [54] [55] [56] Polymorphisms within the CRP promoter regions were associated with plasma CRP levels in AA and European American young adults, 16 and genetic variation within CRP was associated with serum CRP levels in the general population and may be associated with prevalent coronary heart disease. 15 We did not find IL6 and TNF-a, which are known to stimulate CRP production by the liver, 57 to be under the identified LOD score peaks.
The FGA, FGB and FGG loci are on chromosome 4q28, but we did not detect a linkage signal on this chromosomal region in either ethnicity. Soria et al. 58 found suggestive evidence of linkage for fibrinogen on chromosomes 12q24 (LOD ¼ 2.1, between D12S79 and D12S1718) and 14q11 (LOD ¼ 3.12, between D14S72 and D14S50). Fine mapping of the chromosome 12q24 locus suggested TCF1, which encodes a hepatocyte transcription factor, as a potential candidate gene that influences fibrinogen level. 58 We found suggestive evidence for linkage for the bivariate CRP-fibrinogen trait in AA subjects in the same locus on chromosome 12q24 (152.16 cM) (Table 4) . However, in our study, the 12q24 region was not linked to either trait separately. Although both LOD scores were fairly modest (1.95 and 1.5, respectively), similar suggestive linkage for fibrinogen was found on chromosome 17q24 in our current study and by Yang et al. 52 Further fine mapping of the regions that replicate in different studies and a positional candidate gene approach such as that of Soria et al. 58 may identify novel genes that regulate CRP and fibrinogen levels. In the present study, several potential candidate genes that may influence fibrinogen levels were identified under the linkage signals for plasma fibrinogen (Table 4) . These genes may influence the expression, activation and degradation of fibrinogen, and thereby affect plasma fibrinogen levels.
We found no overlap in regions with LOD scores 41.30 for CRP and fibrinogen between the two ethnic groups, indicating that genetic regions that influence CRP or fibrinogen differ in the two ethnic groups and/or that gene-environment interactions are unique to the two groups. Our results and those of others suggest that linkage analyses may not have the power to detect genomic regions with small effects on fibrinogen or CRP levels. 52 The advantage of linkage analyses for complex diseases is the potential to identify new candidate genes that may have been unsuspected, but a disadvantage is the weak power to detect small gene effects. 59 Additional strategies that increase the power of linkage analyses to detect such effects need to be considered. These include larger samples, populations with similar genetic backgrounds and subgroups 
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Linkage analyses for inflammatory markers K Ding et al with more homogeneous pathophysiology. Bivariate linkage analyses of correlated traits were employed in our study to obtain greater statistical power to identify genetic loci with effects too small to be detected in univariate linkage analysis. 25, 60 Plasma CRP and fibrinogen levels are heritable traits that are genetically correlated in AA and NHW hypertensive sibships. Using univariate and bivariate linkage analyses, we identified several chromosomal regions that may harbour genes influencing CRP and fibrinogen levels as well as regions that may have pleiotropic effects on the two traits. Further fine mapping of the regions may identify novel genes that regulate CRP and/or fibrinogen levels, providing new insights into CVD pathophysiology, disease risk stratification and disease prevention.
